Ozempic and Wegovy contain the same active molecule, semaglutide, but they are approved and labelled for different clinical uses in the United States. At Longevity Benchmark, we compare what the approved labelling and the published clinical trials actually establish. Ozempic carries an approved use for type 2 diabetes, while Wegovy carries an approved use for chronic weight management.

Both medications are manufactured by Novo Nordisk and are administered once weekly by subcutaneous injection. While both products share an identical active chemical compound, each brand name corresponds to its own prescribing information document, distinct clinical trial datasets, and specific studied dose strengths.

The Verdict

Ozempic and Wegovy deliver the identical active GLP-1 receptor agonist, semaglutide, manufactured by Novo Nordisk, but they represent distinct clinical options defined by separate approved uses and official prescribing information documents. Ozempic carries an approved indication for type 2 diabetes, while Wegovy carries an approved indication for chronic weight management. STEP 1 and SELECT studied semaglutide 2.4 mg, the dose strength associated with the weight-management labelling; SURPASS-2 used semaglutide 1 mg as a comparator arm in a tirzepatide trial. Neither brand serves as an automatic default choice over the other. Specific dose strengths, escalation schedules, retail prices, and insurance coverage terms cannot be verified on this page and must be confirmed through official product documentation. The choice between these semaglutide brands depends on clinical diagnosis, documented health parameters, and treatment goals determined collaboratively by the patient and their licensed healthcare prescriber.

Ozempic vs Wegovy, Side by Side

AttributeOzempicWegovy
Active molecule Semaglutide Semaglutide
Receptor target GLP-1 receptor agonist GLP-1 receptor agonist
Manufacturer Novo Nordisk Novo Nordisk
Approved use category Type 2 diabetes Chronic weight management
Administration route Subcutaneous injection once weekly Subcutaneous injection once weekly
Prescribing information document Ozempic prescribing information Wegovy prescribing information
Key clinical trials cited on this page No Ozempic trial is cited on this page STEP 1 and SELECT
Most common reported adverse events Gastrointestinal events including nausea, diarrhea, and vomiting Gastrointestinal events including nausea, diarrhea, and vomiting
Boxed warning Thyroid C-cell tumours observed in rodents Thyroid C-cell tumours observed in rodents

One Molecule with Two Approved Uses

Ozempic and Wegovy share the exact same active pharmaceutical molecule, semaglutide, but they are approved for separate medical indications. Semaglutide is a GLP-1 receptor agonist developed and manufactured by Novo Nordisk. Both formulations are administered once weekly through subcutaneous injection. Despite sharing an identical active ingredient, the two products are marketed as separate brands that correspond to distinct clinical trial programs and regulatory indications.

The approved use category for Ozempic is type 2 diabetes. In contrast, the approved use category for Wegovy is chronic weight management. The difference in approved uses determines how each medication was assessed in research, the specific trial endpoints used to demonstrate efficacy, and the clinical indications printed in the official documentation.

Understanding this separation prevents common misunderstandings regarding clinical indications and trial findings. For additional context on how metabolic markers relate to weight and glucose regulation, readers can explore our guides on A1c vs fasting glucose and insulin resistance and weight loss.

Why a Brand Name Is Tied to an Approved Indication

Each brand name corresponds to its own official prescribing information document with its own approved indication. The Ozempic prescribing information outlines the approved use for type 2 diabetes, whereas the Wegovy prescribing information outlines the approved use for chronic weight management. These documents function as independent regulatory records that govern how the products are labelled and prescribed in clinical practice.

Information regarding retail pricing, insurance formulary tiers, prior authorization criteria, copay cards, and pharmacy inventory is outside what this page can verify. Readers should consult the prescribing information for each brand and their prescriber.

  • Ozempic Prescribing Information. Governs the clinical use of semaglutide for type 2 diabetes, presenting efficacy and safety data derived from diabetes trial populations.
  • Wegovy Prescribing Information. Governs the clinical use of semaglutide for chronic weight management, presenting data derived from trial populations with elevated body mass index.
  • Shared Labelling Elements. Both prescribing information documents carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies.

Weight Loss Outcomes in Published Clinical Trials

Evidence for weight reduction with semaglutide comes primarily from dedicated trials in populations without diabetes, most notably STEP 1. In the STEP 1 trial, published in 2021 and funded by Novo Nordisk, researchers evaluated semaglutide at a dose of 2.4 mg once weekly versus placebo over 68 weeks. The trial enrolled 1,961 adults who had a body mass index of 30 or greater, or 27 or greater with a weight-related coexisting condition, while excluding individuals with diabetes. All participants received a lifestyle intervention alongside the study drug or placebo.

The STEP 1 trial reported a mean weight change of -14.9% with semaglutide 2.4 mg compared to -2.4% with placebo, producing a treatment difference of -12.4 percentage points (95% CI -13.4 to -11.5, P<0.001). In terms of absolute weight, participants in the semaglutide 2.4 mg group had a mean weight change of -15.3 kg versus -2.6 kg in the placebo group. Categorical reductions showed that 86.4% of participants on semaglutide 2.4 mg achieved a weight loss of 5% or more compared to 31.5% on placebo, 69.1% achieved a reduction of 10% or more compared to 12.0% on placebo, and 50.5% reached a reduction of 15% or more compared to 4.9% on placebo.

Weight outcomes for semaglutide were also examined in the open-label SURMOUNT-5 trial, published in 2025 and funded by Eli Lilly. In SURMOUNT-5, 751 adults with obesity but without type 2 diabetes were randomized for 72 weeks to receive either the maximum tolerated dose of semaglutide (1.7 or 2.4 mg once weekly) or the maximum tolerated dose of tirzepatide (10 or 15 mg once weekly). The least-squares mean weight change was -13.7% (95% CI -14.9 to -12.6) with semaglutide versus -20.2% (95% CI -21.4 to -19.1) with tirzepatide (P<0.001). Mean reduction in waist circumference was -13.0 cm with semaglutide compared to -18.4 cm with tirzepatide (P<0.001). Participants on tirzepatide were also more likely to reach categorical weight reductions of at least 10%, 15%, 20%, and 25%. Additional analysis of body composition changes is discussed in our guide on visceral fat.

Cardiovascular Outcomes in the SELECT Trial

Cardiovascular outcome data for semaglutide was evaluated in the randomized, double-blind SELECT trial. Published in 2023 and funded by Novo Nordisk, the SELECT trial investigated semaglutide at a dose of 2.4 mg once weekly versus placebo over a mean follow-up period of 39.8 months. The trial enrolled 17,604 patients aged 45 years or older with preexisting cardiovascular disease and a body mass index of 27 or greater, while excluding individuals with diabetes.

The primary cardiovascular end point occurred in 6.5% of patients in the semaglutide 2.4 mg group compared to 8.0% of patients in the placebo group. The trial reported a hazard ratio of 0.80 (95% CI 0.72 to 0.90, P<0.001). Permanent discontinuation of the trial regimen due to adverse events occurred in 16.6% of patients receiving semaglutide 2.4 mg compared to 8.2% of patients receiving placebo (P<0.001).

The SELECT trial measured outcomes using the 2.4 mg dose strength associated with weight management research. It is important to note that an equivalent published cardiovascular outcomes trial for the dual agonist tirzepatide is not available on equal terms, meaning a direct cardiovascular trial comparison between the two molecules cannot be made at this time.

What the Diabetes Evidence Shows in the SURPASS-2 Trial

Clinical evidence for semaglutide in type 2 diabetes includes findings from the open-label, 40-week SURPASS-2 trial. Published in 2021 and funded by Eli Lilly, the SURPASS-2 trial evaluated 1,879 patients with type 2 diabetes who had a mean baseline HbA1c of 8.28%, a mean age of 56.6 years, and a mean body weight of 93.7 kg. The trial utilized semaglutide at a dose of 1 mg weekly as an active comparator arm against three dose strengths of tirzepatide (5 mg, 10 mg, and 15 mg weekly).

In SURPASS-2, the mean reduction in HbA1c from baseline was -1.86 percentage points in the semaglutide 1 mg group, compared to -2.01 percentage points with tirzepatide 5 mg, -2.24 percentage points with tirzepatide 10 mg, and -2.30 percentage points with tirzepatide 15 mg. The reported treatment differences versus semaglutide 1 mg were -0.15 percentage points (95% CI -0.28 to -0.03, P=0.02) for 5 mg, -0.39 percentage points (95% CI -0.51 to -0.26, P<0.001) for 10 mg, and -0.45 percentage points (95% CI -0.57 to -0.32, P<0.001) for 15 mg.

Body weight reductions in the SURPASS-2 diabetes cohort also showed treatment differences favouring tirzepatide over semaglutide 1 mg by -1.9 kg for the 5 mg group, -3.6 kg for the 10 mg group, and -5.5 kg for the 15 mg group (P<0.001 for all comparisons). These findings reflect semaglutide 1 mg evaluated specifically for glycemic management in a diabetes population rather than the higher dose arms studied in obesity trials. For related discussion on glycemic measures, see our overview of fasting insulin.

Reported Adverse Events and Prescribing Information Warnings

Gastrointestinal symptoms represent the most common adverse events reported across clinical trials of semaglutide. In published trials, these events were primarily mild to moderate in severity and occurred most frequently during the dose escalation phase. In SURPASS-2, nausea was reported in 18% of participants receiving semaglutide 1 mg (compared to 17 to 22% across tirzepatide doses), diarrhea occurred in 12% (compared to 13 to 16% on tirzepatide), and vomiting occurred in 8% (compared to 6 to 10% on tirzepatide).

Hypoglycemia with blood glucose levels below 54 mg/dL in SURPASS-2 occurred in 0.4% of patients receiving semaglutide 1 mg, compared to 0.6% on tirzepatide 5 mg, 0.2% on 10 mg, and 1.7% on 15 mg. Serious adverse events were documented in 3% of the semaglutide 1 mg group and 5 to 7% of participants across the tirzepatide arms. In the STEP 1 trial, 4.5% of participants on semaglutide 2.4 mg permanently discontinued treatment because of gastrointestinal adverse events, compared to 0.8% of participants receiving placebo. In the SELECT trial, adverse events leading to permanent discontinuation occurred in 16.6% of patients on semaglutide 2.4 mg versus 8.2% on placebo.

Both the Ozempic and Wegovy United States prescribing information documents carry a boxed warning regarding thyroid C-cell tumours observed in rodents. Complete contraindications, specific clinical warnings, and comprehensive adverse event reporting are detailed in the official prescribing information for each product. Maintaining adequate nutrition during treatment is discussed further in our guide to nutrient dense foods on GLP-1.

Evidence Standards and Prescribing Decisions

Clinical decisions between semaglutide formulations depend on the patient's diagnosed health condition and alignment with approved prescribing information. The approved use category printed on each brand's labelling is the difference between them; the trials cited on this page are named with the dose strength each one studied.

Decisions regarding whether to initiate or prescribe semaglutide belong entirely to the individual reader and their licensed medical prescriber. Treatment requires clinical evaluation of diagnostic markers, medical history, and relevant clinical documentation rather than assuming the two brand names are interchangeable.

The decision belongs to the reader and their prescriber.

Frequently Asked Questions

Is Ozempic the same drug as Wegovy?

Ozempic and Wegovy contain the same active molecule, semaglutide, and are both manufactured by Novo Nordisk as subcutaneous injections administered once weekly. However, they are labelled for different approved medical uses. Ozempic is approved for type 2 diabetes, while Wegovy is approved for chronic weight management. Each product has its own prescribing information document and was evaluated in separate clinical trial programs. Determining which medication is clinically appropriate depends on a patient's medical diagnosis and consultation with a licensed healthcare provider.

Why does the same molecule have two names?

The same active molecule carries two brand names because Novo Nordisk registered and labelled each product for a distinct approved use. Ozempic was evaluated and labelled for type 2 diabetes, with clinical trials focusing on glycemic management parameters such as HbA1c reduction. Wegovy was evaluated and labelled for chronic weight management, supported by trials evaluating body weight change in individuals with elevated body mass index. Having separate brand names links each product directly to its approved indication, evaluated trial arms, and official prescribing information.

Can Ozempic be used for weight loss?

Ozempic carries an approved use for type 2 diabetes, whereas chronic weight management is the approved indication for Wegovy. Clinical trial evidence for weight reduction in individuals without diabetes was generated primarily under the clinical development program associated with Wegovy, such as the STEP 1 trial using semaglutide 2.4 mg. Any clinical decision to prescribe medication outside its approved indication is a matter strictly between an individual patient and their licensed healthcare provider based on documented medical circumstances.

Which one has the cardiovascular trial behind it?

The cardiovascular outcomes trial cited on this page is the SELECT trial, which evaluated semaglutide 2.4 mg weekly in patients without diabetes. In the SELECT trial of 17,604 patients aged 45 years or older with preexisting cardiovascular disease and a BMI of 27 or greater, semaglutide 2.4 mg demonstrated a hazard ratio of 0.80 (95% CI 0.72 to 0.90, P<0.001) for the primary cardiovascular end point compared to placebo over a mean follow-up of 39.8 months. The 2.4 mg dose strength evaluated in SELECT corresponds to the dose studied in the Wegovy clinical development program.

Is Rybelsus the same thing in a tablet?

Rybelsus contains semaglutide, the same active ingredient found in Ozempic and Wegovy, but is formulated as an oral tablet rather than an injectable solution. Manufactured by Novo Nordisk, Rybelsus carries an approved use for type 2 diabetes. Full details regarding its formulation, indications, and clinical warnings are set out in its official prescribing information.

Do Ozempic and Wegovy have different side effects?

Because Ozempic and Wegovy contain the same active molecule, their reported adverse event profiles are similar across clinical trials. Gastrointestinal symptoms, including nausea, diarrhea, and vomiting, are the most common adverse events reported for both drugs, occurring primarily during dose escalation. In SURPASS-2, nausea occurred in 18% of participants receiving semaglutide 1 mg, while in STEP 1, 4.5% of participants discontinued semaglutide 2.4 mg due to gastrointestinal events. Both brand labels also carry a boxed warning regarding rodent thyroid C-cell tumours.

What are the maximum strengths of each?

Approved product strengths and maintenance dosing guidelines are not figures this page can verify, as they are established within the official prescribing information documents for each brand. In the published clinical trials cited on this page, semaglutide was evaluated at doses of 1 mg weekly in the SURPASS-2 diabetes trial, and up to 2.4 mg weekly in the STEP 1 and SELECT trials. Readers should review the official prescribing information for Ozempic and Wegovy or speak with their prescribing healthcare provider to verify current product strengths.

Related